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OBJECTIVE: Evaluate the effectiveness of collabora-
tive management of hypertension by primary care-
pharmacist teams in community-based clinics.
STUDY DESIGN: A 12-month prospective, single-blind,
randomized, controlled trial in the Providence Primary
Care Research Network of patients with hypertension
and uncontrolled blood pressure.
METHODS: As compared to usual primary care, inter-
vention consisted of pharmacy practitioners participat-
ing in the active management of hypertension in the
primary care office according to established collabora-
tive treatment protocols. At baseline, there was no
significant difference in blood pressure between groups.
Primary outcome measures were the differences in
mean systolic and diastolic blood pressures between
arms at study end. Secondary measures included blood
pressure goal attainment (<140/90 mmHg), hyperten-
sion-related knowledge, medication adherence, home
blood pressure monitoring, resource utilization, quality
of life, and satisfaction.
RESULTS: A total of 463 subjects were enrolled (n=233
control, n=230 intervention). Subjects receiving the
intervention achieved significantly lower systolic (p=
0.007) and diastolic (p=0.002) blood pressures com-
pared to control (137/75 mmHg vs. 143/78 mmHg). In
addition, 62% of intervention subjects achieved target
blood pressure compared to 44% of control subjects (p=
0.003). The intervention group received more total office
visits (7.2 vs. 4.9, p<0.0001), however had fewer
physician visits (3.2 vs. 4.7, p<0.0001) compared to
control. Intervention subjects were prescribed more
antihypertensive medications (2.7 vs. 2.4, p=0.02), but
did not take more antihypertensive pills per day (2.4 vs.
2.5, p=0.87). There were minimal differences between
groups in hypertension-related knowledge, medication
adherence, quality of life, or satisfaction.
CONCLUSIONS: Patients randomized to collaborative
primary care-pharmacist hypertension management
achieved significantly better blood pressure control
compared to usual care with no difference in quality of
life or satisfaction.
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INTRODUCTION
In 2007, the Association of Medical Colleges published “Recent
Studies and Reports on Physician Shortages in the U.S.”
1 The
projected shortage of physicians will be an estimated 55,000 to
200,000 by 2020.
2–4 The predicted mismatch between physi-
cian supply and patient demand is heavily influenced by the
aging US population and the increased burden of chronic
illness. Although some experts call for an increase in medical
school admissions, others suggest this solution perpetuates
past healthcare delivery design and ignores the opportunity to
reconfigure the system based on the needs of the future.
5
Specifically, Greenberg, et al. suggest that care of the aging
population with widespread chronic illness should rely on
coordination of care between physicians and non-physician
healthcare professionals to facilitate improved disease man-
agement.
5 However, there is a paucity of large, multi-site,
randomized controlled studies assessing the value of allied
healthcare professionals to help inform healthcare redesign.
Hypertension is an appropriate target for team-based
disease management based on its high prevalence (affects 50
million Americans) and poor disease control (66% of patients
fail to achieve a target <140/90 mmHg).
6 Although papers
describing the potential role of clinical pharmacists in the care
of hypertension date back more than 30 years,
7 this approach
has not been widely disseminated outside of closed delivery
systems, such as the Veterans Administration. Optimal man-
agement of hypertension relies on patient education, encour-
agement of self-management and lifestyle modification, use of
antihypertensive agents and blood pressure monitoring.
6
When patients do not reach target blood pressure, regular
follow-up with a vigorous stepped approach to antihyperten-
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1966sive therapy is recommended.
8 These elements of hypertension
management are within the scope and training of all Doctors of
Pharmacy completing accredited residency training in primary
care.
9 A systematic review evaluating pharmacists in expanded
patient care roles found improved outcomes in chronic health
conditions, including hypertension.
10
The purpose of this study was to address important
evidence gaps by assessing the impact of co-located physi-
cian-pharmacist team-based care on blood pressure control,
quality of life and patient satisfaction in patients cared for by
all physicians practicing in multiple community-based clinics
over a 1-year period.
METHODS
This study was a 12-month, single-blind, randomized, con-
trolled study, approved by the organizational institutional
review board.
Study Site and Population. The study was conducted within the
Providence Primary Care Research Network in Oregon, which
is part of a not-for-profit integrated delivery system. All
Network community-based primary care clinics were included
(n=9), with the exception of academic teaching clinics (n=4).
Participating clinics comprised approximately 80 physicians
caring for 110,000 patients of mixed insurance status.
To identify candidates with known hypertension and un-
controlled blood pressure, the Network’s electronic medical
record (EMR) database was queried (February 2000) for
patients with an office visit within the past 2 years, a problem
list entry of hypertension (ICD-9 of 410.*), and a last systolic
blood pressure ≥160 mmHg and/or a last diastolic blood
pressure ≥100 mmHg. Patients with mildly uncontrolled blood
pressure (140–159/90–99 mmHg) were offered participation in
a parallel study evaluating mailed patient self-management
materials (data published elsewhere).
11
Subjects were excluded if there was no blood pressure
reading in the chart in the previous 2 years, they had attended
a visit with a pharmacy practitioner in the previous 6 months,
or they had transferred care out of the Network.
All eligible candidates received a mailed invitation for
participation. Interested candidates provided consent by re-
turn postcard or phone. At the time consent was received by
research staff, subjects were randomly assigned, with equal
allocation and without restrictions, to intervention or control
using a computer-generated random sequence. Based on the
nature of the intervention, participant blinding was not
possible. All subjects were mailed hypertension educational
materials
11 in order to assure similar baseline awareness of
hypertension self-management principles between groups.
Intervention. Subjects allocated to usual care were instructed
to continue their normal schedule of medical care. The primary
care physician was also provided a list of subjects allocated to
usual care. Out of concern, subjects with an entry BP≥180/
110 mmHg, based on last measurement in the EMR, were
scheduled for an appointment with their primary care provider
if a future appointment did not already exist.
Subjects allocated to the intervention were scheduled for an
appointment in their primary care clinic with any one of five
Network-employed pharmacy practitioners. Each pharmacist
had a post-baccalaureate doctor of pharmacy degree, 1 to
2 years of ambulatory medicine residency training, and was
board certified in pharmacotherapy. No additional training was
provided in preparation for this study. During the initial visit,
pharmacists described the physician-pharmacist collaborative
model of care. Consistent with Network-approved collaborative
hypertension management guidelines, the pharmacists
reviewed subjects’ medications and lifestyle habits, assessed
vital signs, screened for adverse drug reactions, identified
barriers to adherence, provided education, optimized the
antihypertensive regimen, and scheduled follow-up appoint-
ments as judged necessary. Antihypertensive regimen optimi-
zation included alterations in antihypertensive regimens to
titrate the dose of an existing medication, add a new agent,
switch a medication, or consolidate antihypertensive therapy.
The pharmacist had access to patients’ medical records to
assist medication selection and dosing, as well as access to the
primary care physician (PCP) to discuss the hypertension
treatment plan or other medical issues as needed. Following
each interaction, a note was documented in the EMR and
forwarded to the PCP for approval and co-signature.
Outcome Measures
Clinical. The primary outcome was the difference in mean
systolic and diastolic blood pressures between the team-based
care arm (intervention) and the usual care arm (control) at
study end. Effectiveness of hypertension management was also
evaluated as the proportion of subjects in each group
achieving a target blood pressure <140/90 mmHg. At study
end, subjects attended open clinic sessions in which blood
pressure was assessed by registered nurses blinded to
subjects’ randomization allocation. Three blood pressure
measurements were taken according to study protocol using
an appropriately sized cuff and standard mercury
sphygmomanometer after the subject had been sitting quietly
for at least 5 min with no less than 5 min between
measurements. The mean of the second and third pressures
was used for analysis. If a subject failed to attend the exit visit
despite multiple contact attempts (i.e., drop out), a chart
review was conducted to extract the last available clinic blood
pressure for intention-to-treat (ITT) analysis.
Self-management. Patient self-management knowledge and
behavior measures were assessed by a self-administered
questionnaire completed at baseline and exit study visit. An
internally designed ten-item instrument was tested for
readability, face and content validity with local experts, and
for internal validity in a sample of patients.
11 An aggregate
score was calculated based on the number of correctly
answered questions. Assessment of medication adherence
consisted of four validated patient self-reported questions.
12
Subjects were also asked whether they used a home blood
pressure monitoring device and, if so, whether they recorded
their readings.
Resource Utilization. Healthcare utilization information was
collected by chart audit during the period of time from
subject consent through the date of the exit visit. Information
on the number and purpose for each office visit with a primary
1967 Hunt et al.: Physician-pharmacist collaboration and hypertension management JGIMcare provider and/or a pharmacist was extracted. This
information was reported in three categories: (1) primary care
provider, (2) pharmacist, and (3) the sum of total clinic visits.
Information was also collected on antihypertensive use
including drug class(es), generic status, dosages per day, and
number of pills per day.
Quality of Life and Satisfaction. Subjects’ health status was
evaluated at the exit visit using the Medical Outcomes Study
SF-36 survey reporting scaled results for the eight domains, as
well as physical and mental health composite scores.
13 In
addition, subjects were asked to rate their satisfaction with
components of healthcare delivery and hypertension
treatment. The general healthcare domain included six
questions about satisfaction with provider, health plan, and
care delivery (e.g., access, service). The hypertension-specific
domain included five questions inquiring about satisfaction
with explanations of hypertension, antihypertensive
medications, cost of antihypertensive medications, time spent
discussing hypertension, and satisfaction with hypertension
monitoring.
Statistical Analysis. A sample size of 151 subjects per arm was
required to detect a 3-mmHg difference in mean systolic and
diastolic blood pressures between intervention and control
groups for 90% power at a significance level of p<0.05 (two-
sided), assuming a standard deviation for systolic and diastolic
blood pressures of 8 mmHg.
The primary outcomes of systolic and diastolic blood
pressure between groups at the study end were compared
using unpaired t-tests. Other continuous data were described
by mean (standard deviation) and were compared using paired
t-test for within-group baseline-to-final assessment compar-
isons and unpaired t-tests for between-group analysis. Asso-
ciation between continuous variables was measured using
correlation analysis. Categorical data were described by percen-
tages and were compared by chi-square tests with continuity
correction or Fisher’s exact test, as appropriate. Repeated
measures analyses of variance were used to evaluate continuous
variables such as quality-of-life composite scores, hypertension
knowledge, and patient satisfaction. The Mann-Whitney U test
was used for between-group comparisons for variables that were
not normally distributed. The Wilcoxon signed-ranks test for
paired samples was used for within-group comparisons.
14 The
significance level was set at 0.05. All analyses were completed
using SAS version 9.1.
15
RESULTS
A total of 2,901 candidates were identified as eligible and
mailed an invitation to participate. Of the 463 subjects
consenting to participate (16% response rate), 233 were
allocated to usual care, and 230 were allocated to team-based
care (Fig. 1). The intervention and control arms were compa-
rable with respect to age, gender, education, insurance, body
mass index, smoking status, prevalence of chronic illness, and
baseline blood pressure with the exception of history of stroke
(Table 1). As seen in Fig. 1, a total of 191 subjects (41%)
withdrew from the study following randomization, 88 (38.3%)
from the intervention arm and 103 (44.2%) from the control
arm. Of subjects unavailable at the exit visit, all had docu-
mented blood pressures in the chart, with the exception of
seven subjects (n=4 control; n=3 intervention), in which case
the last clinic blood pressures were carried forward. Detailed
analyses published elsewhere demonstrate that the groups
remained comparable despite withdrawal.
16
Clinical. Between-group analysis revealed significant differences
in mean systolic (Δ=6 mmHg, p=0.007) and diastolic (Δ=
3 mmHg, p=0.003) blood pressures between groups at study
end with subjects receiving team-based care achieving lower
systolic and diastolic blood pressures as compared to control
(Table 2). In addition, 62% (88/142) of intervention subjects had
a blood pressure <140/90 mmHg at the exit visit as compared to
44% (57/130) of control subjects (p=0.003). The odds of
achieving blood pressure target in the intervention group were
2.08 times higher than the control group (95% CI=1.29–3.38).
These differences remained significant when data were assessed
by intention-to-treat analysis.
Self-management. At study end, there was no difference in
hypertension-related knowledge scores between study arms
with a mean score of 7.5 (SD=1.86) in the control arm and 7.9
(SD=1.65) in the intervention arm (p=0.27). There was a
statistically significant interaction between time and group
(p=0.0013) such that hypertension-related knowledge
increased in the intervention arm and decreased in the
control arm from study start to end. Analysis was completed
to evaluate the relationship between hypertension knowledge
and achievement of blood pressure target. Only in the
intervention arm, there was a significant difference in
hypertension knowledge between those subjects who achieved
the target blood pressure (mean score=8.2) and those who did
not meet target (mean score=7.4, p=0.03).
There was no difference between groups at study end in the
proportion of subjects reporting high medication adherence
[67% (95/142) intervention vs. 69% (90/130) control, p=0.77].
Within-group analysis indicated no significant increase in
adherence from baseline to final assessment in the control
group (p=0.52). Although subjects receiving the intervention
demonstrated an increase in the high adherence category from
baseline (61% vs. 67%), the difference was not statistically
significant (p=0.08). High medication adherence failed to
predict hypertension goal attainment in either group. At study
end, subjects in the intervention arm reported owning a home
blood pressure monitoring device more frequently than control
subjects [70% (70/99) vs. 51% (46/91), p=0.007]. A higher
proportion of subjects in the intervention arm also reported
recording their home blood pressures in a logbook as com-
pared to control [80% (56/70) vs. 53% (24/46), p=0.002].
Resource Utilization. The totalnumberofclinic visits(physician+
pharmacist) was significantly higher in the intervention arm as
compared to control (Table 3). However, the number of physician
visits was significantly lower in the intervention arm (3.2 vs. 4.7,
p<0.0001). The pharmacy visits (n=26) in the control arm
represented by six subjects were cases where the physician
requested and received a pharmacy consultation for
hypertension. The number of office visits was not statistically
associated with systolic blood pressure in either study arm
1968 Hunt et al.: Physician-pharmacist collaboration and hypertension management JGIM(intervention: r=0.16, p=0.06 and control: r=–0.1, p=0.22), but
was negatively associated with diastolic blood pressure in both
study arms (intervention: r=–0.22, p=0.01 and control: r=–0.18,
p=0.04).
The number of antihypertensive medications increased
significantly in both groups as compared to baseline. Although
subjects in the intervention arm were prescribed a higher
number of antihypertensive medications, there was a small
but insignificant decrease in the daily pill burden of this group
(Table 3). This decrease is explained by a higher penetration of
combined dosage forms in the intervention arm. The interven-
tion group was also significantly more likely to utilize generic
antihypertensive medications.
Quality of Life and Satisfaction. There were no significant
differences between groups with respect to subjects’ quality of
life at follow-up with the exception of the general health
domain (p=0.01), in which scores were slightly higher in the
control group compared to intervention (Table 4). Subjects in
both groups were highly satisfied with the hypertension care
received. The overall satisfaction was 8.5 in the usual care
group compared to 8.6 in the pharmacy group (p=0.75). There
was no significant difference between groups in any of the 11
satisfaction measures and no association between satisfaction
and blood pressure goal attainment (p=0.4).
DISCUSSION
In this study, subjects cared for in the physician-pharmacist
team model were 40% more likely to achieve their goal blood
pressure compared to those cared for by their physician alone.
Among middle-aged patients (i.e., 60–69 years), the 6-mmHg
difference in systolic blood pressure observed in this study
would be expected to yield a 22% reduction in stroke mortality
and a 17% reduction in mortality from ischemic heart
disease.
17 Thus, inclusion of pharmacy practitioners on the
primary care team represents one possible strategy to address
this important public health issue.
Alternatively, elucidating the underlying mechanisms by
which the team-based model achieved superior outcomes in
Eligible patients with last BP>160/100 mmHg 
(n=2,901) 
Active Network patients diagnosed with hypertension 
(n=13,749) 
Consented to participate 
(n=463) 
Enrollment
Randomization
Allocated to usual care 
(n=233) 
Allocated to pharmacist arm 
(n=230) 
Completed  (n=130)
Lost to follow-up  (n=103) 
Completed  (n=142)
Lost to follow-up  (n=88)
Not responded or refused 
participation (n=2,220) 
Figure 1. Patient population eligibility, participation, and randomization flow diagram.
1969 Hunt et al.: Physician-pharmacist collaboration and hypertension management JGIMthis study may facilitate modification of physician practice
within the current healthcare delivery model. National guide-
lines recommend combination therapy as a means to intensify
treatment without increased complexity, a practice implemen-
ted in higher frequency in the team-based arm.
6 Patient cost-
sharing is another factor in medication adherence.
8,18 Although
this study did not assess patient medication cost-share, the
higher generic prescribing rate in the collaborative arm can be
considered a surrogate outcome for cost.
Given the recent findings by Lee et al.
19, it was somewhat
surprising that our study found no difference between arms in
self-reported medication adherence. The four-item self-
reported questionnaire may not have been sensitive enough
to detect a difference if it did exist. Subjects in the team-based
care intervention appeared more engaged in the management
of their hypertension as indicated by increased home blood
pressure monitoring. Another commonly proposed mecha-
nism, not evaluated in this study, is time spent with the
patient during each visit. Moreover, physicians in the study
were undoubtedly confronted with multiple health issues,
while in the team-based model pharmacists were able to focus
more narrowly on management of hypertension.
Although subjects in the intervention arm were prescribed a
higher number of antihypertensive medications, our study
found a negligible impact of the team-based care on patient
quality of life and satisfaction. Other evidence suggests that
the impact of similar pharmacy interventions on patient
quality of life represents a neutral
20,21 to positive effect.
22–24
These results dispel the notion that introducing pharmacists
Table 1. Baseline Demographics
Usual care
(n=233)
Intervention
(n=230)
p-
value
Age-mean (SD)
1 68 (13) 68 (12) 0.86
Gender, male-n (%) 79 (34) 85 (37) 0.46
Insurance-n (%) 0.20
Commercial 72 (31) 84 (37)
Medicare or Medicaid 161 (69) 146 (63)
Education, college
education-n (%)
65 (28) 64 (28) 0.56
Current smoker-n (%) 17 (7) 20 (9) 0.58
Body mass index-mean (SD) 30 (6) 29 (6) 0.40
Co-morbidities-n (%)
Asthma or COPD 27 (12) 27 (12) 0.96
Diabetes 57 (25) 59 (26) 0.77
History of stroke 6 (3) 15 (7) 0.04
Coronary artery disease 43 (18) 46 (20) 0.67
Renal impairment 6 (3) 8 (3) 0.57
One or more chronic
conditions
103 (44) 111 (48) 0.38
Baseline systolic blood
pressure*-mean (SD)
174 (15) 173 (15) 0.43
Baseline diastolic blood
pressure*-mean (SD)
92 (14) 90 (14) 0.21
1SD=standard deviation
*Data acquired from the EMR based on last available blood pressure
value in the 24 months prior to study start
Table 2. Blood Pressure Results
Usual care
(n=130)
Intervention
(n=142)
p-
value
Systolic blood pressure
Result available from study
exit visit-mean (SD)
143 (18) 137 (17) 0.007
ITT
2 (includes last value
carried forward)-mean (SD)
148 (22) 142 (19) 0.002
Diastolic blood pressure
Result available from study
exit visit-mean (SD)
78 (11) 75 (9) 0.003
ITT (includes last value
carried forward)-mean (SD)
80 (12) 77 (10) 0.003
Goal attainment <140/90
mmHg
Result available from
study exit visit-% (N/D)
3
44 (57/130) 62 (88/142) 0.003
ITT (includes last value
carried forward)-% (N/D)
42 (97/233) 54 (125/230) 0.005
2 Intention-to-treat
3 N=numerator, D=denominator
Table 3. Utilization of Office Visits and Antihypertensive
Medications
Usual care
(n=130)
Intervention
(n=142)
p-value
Visits
Office visits-mean (SD)
PCP visits per patient 4.7 (3.1) 3.2 (2.7) <0.0001
Pharmacist visits
per patient
0.2 (0.8) 4.0 (2.3) <0.0001
Total visits per patient 4.9 (3.3) 7.2 (3.3) <0.0001
Hypertension-related
visits-mean (SD)
PCP visits per patient 2.9 (2.2) 1.8 (1.7) <0.0001
Pharmacists visits
per patient
0.2 (0.8) 4.0 (2.3) <0.0001
Total visits per patient 3.1 (2.4) 5.8 (2.6) <0.0001
Pharmacotherapy
Antihypertensive
medications per patient-
mean (SD)
2.4 (1.1) 2.7 (1.2) 0.02
Pills per patient per day-
mean (SD)
2.5 (1.7) 2.4 (1.6) 0.87
Use of generic
antihypertensive agent-%
39.7 50.7 0.008
Table 4. MOS SF-36 Health-Related Quality of Life
Usual care
(n=130)
Intervention
(n=142)
p-value
Quality of life Mean (SD) Mean (SD)
Physical functioning 42 (12) 44 (11) 0.33
Role limitation, physical 49 (7) 48 (7) 0.49
Bodily pain 33 (11) 32 (10) 0.43
General health 44 (6) 42 (6) 0.01*
Vitality (energy and fatigue) 49 (5) 48 (5) 0.20
Social functioning 35 (6) 35 (5) 0.70
Role limitations, emotional 48 (12) 49 (11) 0.32
Mental health 42 (6) 44 (6) 0.15
Physical component
summary (PCS)
42 (6) 41 (6) 0.12
Mental component
summary (MCS)
44 (6) 45 (6) 0.16
Significant at p<0.05
1970 Hunt et al.: Physician-pharmacist collaboration and hypertension management JGIMinto primary care-based chronic disease management risks
jeopardizing the physician-patient relationship.
The fundamental requirements for successful generalization
of this strategy include an adequate workforce of trained
pharmacy practitioners and third party reimbursement. Given
shortfalls in effectiveness of the current healthcare delivery
model,
25 projected physician shortages, and the preponder-
ance of evidence demonstrating improved outcomes when
pharmacists actively participate on patients’ care team,
10 the
inclusion of pharmacists as healthcare providers eligible for
reimbursement for cognitive services warrants serious
consideration.
The results of this study add to a growing body of literature
demonstrating the positive effect of physician-pharmacist
team-based management of hypertension.
7,21,23,26–28 This
study has several strengths, including (1) prospective, ran-
domized, controlled design with evaluator blinding, (2) large
community-based patient population with mixed insurance,
(3) multi-site intervention including all physicians practicing in
nine clinics, (4) involvement of multiple pharmacy practi-
tioners, (5) 12-month study duration, and (6) inclusion of
clinical, patient self-management, economic, quality of life,
and satisfaction outcome measures.
This study is further unique compared to other published
randomized controlled trials evaluating pharmacists’ role in
hypertension management.
7,21,23,26,27,29 In contrast to most
published studies, with the exception of a study conducted in a
VA setting,
28 the pharmacists in this study were empowered to
alter the antihypertensive regimen, according to guidelines,
without consulting the physician in advance. Unlike the VA
study, where pharmacists were located in a separate pharma-
cist-run hypertension clinic,
28 our study evaluated pharma-
cists co-located in the primary care clinic. In this more team-
oriented setting, pharmacists were able to quickly consult the
physician for cases involving complex co-morbidities or the
need for departure from routine guidelines, possibly improving
efficiency, communication, and trust.
In this study, randomization at the patient level, as opposed
to physician or clinic, may have resulted in contamination
bias. Physicians in the study cared for patients in both groups
and, further, co-signed the chart note following every pharma-
cist-patient interaction. In addition, at the request of the
physician, six subjects in the control group received pharmacy
consultation during the study. Although contamination was
considered during study design, investigators recognized that
it would conservatively represent bias toward the null hypoth-
esis. Further, subjects in the usual care arm were offered
active interventions. These interventions included (1) mailed
patient educational information,
11 (2) patient prompts where
there was not a scheduled appointment, and (3) physician
prompts for patients with elevated blood pressure. These
interventions may also have blunted the difference in out-
comes between arms.
In this study, we observed that only 16% of patients with an
active medical record who were solicited to participate via a
mailed invitation responded and subsequently consented. In
practice, unlike the screening and enrollment methods
employed in the study, patients are typically seen by a clinical
pharmacy practitioner following a direct verbal referral by the
PCP. This more traditional referral process might be expected
to yield a higher screening-to-enrollment ratio relative to the
low-touch methodology used here. Effective referral and
enrollment methodologies, as well as patient acceptance of
team-based care involving a pharmacy practitioner, merit
further investigation.
The subject withdrawal rate observed in this study is similar
to the rate reported in other hypertension management
studies.
21,23,27 This study used a low intensity screening and
consent process, which might contribute to the high with-
drawal rate. Analyses published elsewhere demonstrate that
the high withdrawal rate observed in this study did not likely
create an important imbalance in between-group subject
characteristics for those who completed the study.
16 When
subjects who completed and withdrew from the study were
compared, the only factor significantly associated with a higher
withdrawal rate was enrollment in commercial insurance. The
external validity of this study was also not affected by
subject dropout and may even have been enhanced due to
the naturalistic subject recruitment strategy. Regardless of
the type of analysis conducted (analysis of subjects com-
pleting the study or last value carried forward for all
enrolled subjects), a similar reduction in blood pressure
was observed in the intervention group.
CONCLUSION
Involvement of pharmacy practitioners in management of hyper-
tension significantly improves blood pressure control. This
improvement is accomplished without apparent increased com-
plexity or cost to the antihypertensive medication regimen. This
team-based model of hypertension management results in an
increase in total office visits, with a significant decrease in the
number of physician visits. Finally, addition of a pharmacy
practitioner to the healthcare team does not significantly alter
patient quality of life or satisfaction.
Acknowledgement: We would like to extend our thank you to
Kristina Butler, Pharm.D., BCPS (Providence Physician Division,
Department of Pharmacy) for providing patient care services during
this study.
Grant Support: Grant support from Boehringer Ingelheim was
used to fund the cost of the educational mailings and the conduction
of the study.
Conflict of Interest: All data collection, analysis, and reporting
were conducted by the study investigators and the Providence
research staff. The investigators report no other conflict of interest.
Corresponding Author: Jacquelyn S. Hunt, Pharm D MS; Provi-
dence Physician Division, 3601 SW Murray Blvd, Ste 45, Beaverton,
OR 97005, USA (e-mail: jacquelyn.hunt@providence.org).
REFERENCES
1. Association of American Medical Colleges. Recent Studies and Reports
on Physician Shortages in the U.S. Association of American Medical
Colleges; 2007 August.
2. Merrit J, Hawkins J, Miller P. Will the last physician in america please
turn off the lights? A look at America’s looming doctor shortage. Irving:
The MHA Group; 2004.
3. Health Resources and Services and Administration (HRSA). Physician
Supply and Demand: Projections to 2020. Health Resources and
Services and Administration (HRSA); 2006 October.
1971 Hunt et al.: Physician-pharmacist collaboration and hypertension management JGIM4. Council on Graduate Medical Education. Physician Workforce Policy
Guidelines for the U.S. for 2000–2020. US Department of Health and
Human Services; 2005.
5. Greenberg JO, Greenberg H. More physicians are not the answer. Am J
Cardiol. 2007;99(10):1476–8, May 15.
6. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint
National Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure.[see comment]. Hypertension. 2003;42(6):1206–52,
December.
7. McKenney JM, Slining JM, Henderson HR, Devins D, Barr M. The
effect of clinical pharmacy services on patients with essential hyperten-
sion. Circulation. 1973;48(5):1104–11, November.
8. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to
blood pressure-lowering medication in ambulatory care? Systematic
review of randomized controlled trials. [Review] [55 refs]. Arch Intern
Med. 2004;164(7):722–32, April 12.
9. American Society of Health-System Pharmacists. ASHP statement on the
pharmacist’s role in primary care. Am J Health Syst Pharm. 1999;56:1665–
7.
10. Beney J, Bero LA, Bond C. Expanding the roles of outpatient
pharmacists: effects on health services utilisation, costs, and patient
outcomes. Cochrane Database Syst Rev. 2000;3:CD000336.
11. Hunt JS, Siemienczuk J, Touchette D, Payne N. Impact of educational
mailing on the blood pressure of primary care patients with mild
hypertension. J Gen Intern Med. 2004;19(9):925–30, September.
12. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity
of a self-reported measure of medication adherence. Med Care. 1986;24
(1):67–74, January.
13. Ware JE, Kosinski M. SF-36 physical and mental health summary
scales: a manual for users of version 1. 2nd ed. Lincoln, RI: QualMetric
Incorporated; 2001.
14. Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics. Second
ed. Norwalk, CT: Appleton & Lange.; 1994.
15. SAS Institute Inc. SAS/STAT User’s Guide, Version 9.1. 2003. Cary, NC,
SAS Institute. Ref Type: Generic
16. Rozenfeld Y, Hunt JS. Effect of patient withdrawal on a study
evaluating pharmacist management of hypertension. Pharmacotherapy.
2006;26(11):1565–71, November.
17. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific
relevance of usual blood pressure to vascular mortality: a meta-analysis
of individual data for 1 million adults in 61 prospective studies. Lancet.
2002;360(9349):1903–13, December 14.
18. Osterberg L, Blaschke T. Adherence to medication.[see comment].
[Review] [127 refs]. N Engl J Med. 2005;353(5):487–97, August 4.
19. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on
medication adherence and persistence, blood pressure, and low-density
lipoprotein cholesterol: A randomized controlled trial. JAMA. 2006;296
(21):2614–6, December 6.
20. Erickson SR, Slaughter R, Halapy H. Pharmacists’ ability to influence
outcomes of hypertension therapy. Pharmacotherapy. 1997;17(1):140–7,
January.
21. Mehos BM, Saseen JJ, MacLaughlin EJ. Effect of pharmacist inter-
vention and initiation of home blood pressure monitoring in patients
with uncontrolled hypertension. Pharmacotherapy. 2000;20(11):1384–9,
November.
22. Carter BL, Barnette DJ, Chrischilles E, Mazzotti GJ, Asali ZJ.
Evaluation of hypertensive patients after care provided by community
pharmacists in a rural setting. Pharmacotherapy. 1997;17(6):1274–85,
November.
23. Okamoto MP, Nakahiro RK. Pharmacoeconomic evaluation of a phar-
macist-managed hypertension clinic. Pharmacotherapy. 2001;21
(11):1337–44, November.
24. Carter BL, Malone DC, Billups SJ, et al. Interpreting the findings of the
IMPROVE study. Am J Health Syst Pharm. 2001;58(14):1330–7, July 15.
25. Institute of Medicine. Crossing the Quality Chasm: A new Health System
for the 21st Century. Washington, DC: National Academy of Sciences;
2001.
26. B o g d e nP E ,A b b o t tR D ,W i l l i a m s o nP ,O n o p aJ K ,K o o n t zL M .
Comparing standard care with a physician and pharmacist team
approach for uncontrolled hypertension. J Gen Intern Med. 1998;13
(11):740–5, November.
27. Borenstein JE, Graber G, Saltiel E, et al. Physician-pharmacist
comanagement of hypertension: a randomized, comparative trial. Phar-
macotherapy. 2003;23(2):209–16, February.
28. Vivian EM. Improving blood pressure control in a pharmacist-managed
hypertension clinic. Pharmacotherapy. 2002;22(12):1533–40, December.
29. Sookaneknun P, Richards RM, Sanguansermsri J, Teerasut C.
Pharmacist involvement in primary care improves hypertensive
patient clinical outcomes. Ann Pharmacother. 2004;38(12):2023–8,
December.
1972 Hunt et al.: Physician-pharmacist collaboration and hypertension management JGIM